The Canadian market for Renin-Angiotensin System (RAS) medicines shows a declining trend from 2024 to 2028, with sales decreasing from $721.2 million in 2024 to $609.2 million in 2028. This trend indicates a consistent contraction, with an average year-on-year decrease of approximately 4.1%. In 2023, RAS medicines stood at a slightly higher value than in subsequent years, reflecting a peak before the forecasted decline.

Future trends to watch for include:

Potential impact of generic drug entries, influencing pricing and market share.
Emerging alternative treatments or innovative therapies that could reduce the demand for traditional RAS medicines.
Regulatory changes and healthcare policies affecting drug pricing and accessibility.
Shifts in population demographics potentially altering the prevalence of conditions treated by RAS medicines.